Lincoln Pharmaceuticals Ltd. launches Antimalarial drug ‘ARH 1’ developed with innovative dose optimization technology, for the first time in the world

Lincoln Pharmaceuticals Ltd. (LPL), Ahmedabad based world class pharmaceutical company once again causes a stir with the launch of Antimalarial drug ‘ARH 1’, developed using innovative technology known as Dose Optimization Technology under the Novel Drug Delivery System (NDDS), for the first time in the world. While mainstay treatment for malaria is complex and difficult to administer, ARH 1 is simpler and much more yielding making it easier for malarial patients to tolerate and recuperate from this disease.  ARH 1 will be particularly helpful for the treatment of severe malaria, Falciparum. The drug is more effective with less volume, less pain and low viscosity providing better compliance to malarial patients.

Every year, millions in India alone fall victim to malaria, out of which 50% of the cases are Falciparum Malaria; the most dangerous and life threatening form of malaria. ARH 1 will be available in injection form making it the Drug of Choice for the treatment of Malaria. ARH 1 contains a-b Arteether 150mg/ml (Arteether is a fast acting blood schizonticidal agent that kills malarial parasite) and is manufactured using an innovative solubility technique which gives patients suffering from malaria the desired results. The launch of the ARH 1 Injection will provide better treatment to millions of Indian’s suffering from the disease.

LPL conducted multi-centric trials on the efficacy and safety of the new and innovative ARH 1 injection at leading hospitals across the country. Clinical trials on more than 280 patients have proven the efficacy of this product in comparison to leading brands available in the market.

Speaking on the occasion Mahendra G Patel, MD, Lincoln Pharmaceutical Ltd. said, “Lincoln Pharmaceutical Ltd. is about providing healthcare for all, the launch of ARH 1is yet another innovative drug that has been created in line with our mantra and we are very excited about its introduction. With ARH 1 we are now the first company in India to provide an enhanced treatment for severe malaria. We at Lincoln Pharmaceutical Ltd are very happy to be a part of making lives of malarial patients easier with better healthcare products.” He further added, “ARH 1 will further strengthen our position in the Indian pharmaceutical industry and will go a long way in establishing Lincoln Pharmaceutical as one of the leading players in the industry”.

LPL has applied for a patent of ‘ARH 1’ in India as well as internationally.

For additional information contact:

Atul Malikram

9827092823